Premium
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV‐infected liver graft recipients
Author(s) -
Stärkel Peter,
Stoffel Michel,
Lerut Jan,
Horsmans Yves
Publication year - 2005
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.20464
Subject(s) - medicine , hbsag , lamivudine , vaccination , immunosuppression , hepatitis b virus , fulminant hepatitis , hepatitis b , liver transplantation , immunology , titer , gastroenterology , transplantation , antibody , virology , hepatitis , virus
Strategies using lamivudine and hepatitis B immunoglobulins (HBIg) for prevention of hepatitis B virus (HBV) reinfection after liver transplantation (LT) are expensive since life‐long treatment is needed. We evaluated the possibility to obtain protective hepatitis B surface antigen (HBsAg) antibody (anti‐HBs) titers after LT and to discontinue HBIg prophylaxis after a reinforced course of vaccination against HBV using an experimental adjuvant HBsAg / AS04 vaccine (GlaxoSmithKline Biologicals [GSK], Rixensart, Belgium) in patients transplanted for hepatitis B. Fifteen LT patients on stable low‐level immunosuppression were vaccinated with a double dose of the vaccine at 0, 1, 2, 6, and 12 months: 5 patients were transplanted for nonviral diseases and 10 patients were transplanted for HBV on HBIg monotherapy. HBIg were continued during baseline vaccination (0, 1, and 2 months) and when anti‐HBs titers determined every 6 weeks dropped below 150 IU/L. Overall follow‐up was 18 months. Sustained long‐term response to vaccination was defined as anti‐HBs titers >500 IU/L without further need for HBIg administration during a follow‐up period of at least 12 months. Overall sustained response to vaccination was 53% (8 / 15 patients); 80% (4 / 5 patients) in the nonviral disease group and 40% (4 / 10 patients) in the HBV group (2 /2 fulminant and 2/8 chronically infected patients) developed a sustained long‐term response and were completely free of HBIg at the end of the 18‐month follow‐up. No HBV recurrence, rejection episodes, or side effects occurred during the follow‐up. In conclusion, protective anti‐HBs titers were obtained in a substantial number of LT patients following a reinforced course of HBV vaccination with vaccines containing new immunostimulating adjuvants. Vaccination seems well tolerated and safe and allows long‐term discontinuation of HBIg. (Liver Transpl 2005;11:1228–1234.)